Hiv/Aids Drugs Market Size, Share and Industry Analysis By Drug Class (Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors, Combination HIV Medicines, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Hiv/Aids Drugs Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Hiv/Aids Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Hiv/Aids Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Hiv/Aids Drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Hiv/Aids Drugs Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Hiv/Aids Drugs Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
ViiV Healthcare
  
Gilead Sciences, Inc.
  
Merck Sharp & Dohme Corp.
  
Bristol-Myers Squibb Company
  
Janssen Pharmaceuticals, Inc.
  
Theratechnologies Inc.
  
Mylan Pharmaceuticals Inc.
  
Genentech, Inc.
  
AbbVie Inc.

Report Coverage

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2018, an estimated 37.9 million people globally were living with HIV. Out of these infected individuals, an estimated 23.3 million people were accessing antiretroviral therapy. This large patient pool suffering from HIV/AIDS, combined with a longer treatment duration of drugs, and the increasing awareness and efficiency of drugs, is leading to rising demand for HIV/AIDS drugs globally.

The introduction of new products in the market, along with an increasing number of patients undergoing HIV/AIDS globally is projected to further augment the demand for HIV/AIDS drugs market during the forecast period.
The report provides qualitative and quantitative insights on the HIV/AIDS drugs market industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market segments include drug class, distribution channel, and geography. On the drug class, the global HIV/AIDS drugs market segments include non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, combination HIV medicines, and others.

Based on distribution channel, the global market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.

Along with this, the report analysis includes HIV drugs market dynamics and competitive landscape. Various key insights provided in the report are the epidemiology of HIV/AIDS by key countries, overview of pipeline analysis, regulatory scenario by key countries, pricing analysis of key players, key strategies employed by market leaders in various regions, overview of new product launches, and others.

SEGMENTATION

By Drug Class

  
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  
Integrase Inhibitors
  
Combination HIV Medicines
  
Others

By Distribution Channel

  
Hospital Pharmacies
  
Retail Pharmacies
  
Online Pharmacies
  
Others

By Geography

  
North America (the USA and Canada)
  
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  
Rest of the World

Key Industry Developments

In July 2019, Merck unveiled early and positive results about its HIV new drug candidate called MK-8591, which the company says can be a game changer in the HIV/AIDS drugs market

In April 2019, the U.S. FDA announced the approval of ViiV Healthcares Dovato (dolutegravir/lamivudine), the first ever once daily, single tablet, two drug regiment for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and having no known resistance to either DTG or 3TC

In June 2018, the U.S. FDA approved Mercks DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), an once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO (doravirine), a Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI), both approved for the treatment of HIV-1